Combined use of VII polypeptides and factor VIII polypeptides
OwnerJens Bjerre Knudsen, Ulla Hedner +1inventors
InventorsJens Bjerre Knudsen, Ulla Hedner, Rasmus Rojkjaer
Life of this patent
Estimating the term…
Abstract
The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical use as well as methods for prevention or treatment of bleeding episodes in subjects.
Claims62
A pharmaceutical composition comprising (i) a preparation of factor VII or a factor VII-related polypeptide, and (ii) a preparation of factor VIII or a factor VIII-related polypeptide.
A kit of parts containing a treatment for bleeding episodes comprising
- a) A first amount of a preparation of a factor VII or factor VII-related polypeptide and a pharmaceutically acceptable carrier in a first unit dosage form;
- b) A second amount of a preparation of a factor VIII or factor VIII-related polypeptide and a pharmaceutically acceptable carrier in a second unit dosage form;
- and
- c) Container means for containing said first and second dosage forms,
- Wherein said first and second amounts together are effective to treat a bleeding episode.
Use of a preparation of a factor VII or factor VII-related polypeptide in combination with a preparation of a factor VIII or a factor VIII-related polypeptide for the manufacture of a medicament for treating bleeding episodes in a subject.
Use of a preparation of a factor VII or factor VII-related polypeptide in combination with a preparation of a factor VIII or factor VIII-related polypeptide for the manufacture of a medicament for reducing clotting time.
Use of a preparation of a factor VII or factor VII-related polypeptide in combination with a preparation of a factor VIII or factor VIII-related polypeptide for the manufacture of a medicament for prolonging the clot lysis time.
Use of a preparation of a factor VII or factor VII-related polypeptide in combination with a preparation of a factor VIII or factor VIII-related polypeptide for the manufacture of a medicament for increasing clot strength.
Use of a preparation of a factor VII or factor VII-related polypeptide in combination with a preparation of a factor VIII or factor VIII-related polypeptide for the manufacture of a medicament for enhancing fibrin clot formation.
A method for treating bleeding episodes in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide, wherein the first and second amount together are effective to treat bleedings.
A method for reducing clotting time in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide wherein the first and second amount together are effective to reduce clotting time.
A method to enhance haemostasis in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide wherein the first and second amount together are effective to enhance haemostasis.
A method for reducing the number of administrations of coagulation factor protein needed to arrest bleeding and maintain haemostasis in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide wherein the first and second amount together are effective to arrest bleeding and maintain haemostasis.
A method for reducing the amount of administered coagulation factor protein needed to arrest bleeding and maintain haemostasis in a subject, the method comprising administering to a subject in need thereof a first amount of a preparation of a factor VII or factor VII-related polypeptide and a second amount of a preparation of a factor VIII or factor VIII-related polypeptide wherein the first and second amount together are effective to arrest bleeding and maintain haemostasis.
A kit containing a treatment for bleeding episodes comprising
- a) A first amount of a factor VII or factor VII-related polypeptide and a second amount of a factor VIII or factor VIII-related polypeptide and a pharmaceutically acceptable carrier in a one-unit dosage form;
- and
- b) Container means for containing said one-unit dosage form,
- Wherein said first and second amounts together are effective to treat bleeding episodes.
Dependencies are inferred from the claim text.